TNFRSF10A and colorectal carcinoma: Co-expression of TRAIL-R1 and TRAIL-R2 was seen in 56.85% of the CRC( 191/336) and was associated with a good survival (p = 0.0107; see Additional File 4) which remained significant in multivariate analysis (Cox proportional hazards) with TRAIL-R1/R2 co-expression, tumor grade, tumor stage, age and gender as variables (see Additional File 1 Table S3).